Immunocore expands existing discovery collaboration with Genentech

Privately-held UK-based Immunocore, a T Cell Receptor (TCR) biotech company, today announces it has entered into a new partnership with Genentech, a part of Swiss pharma giant Roche (ROG: SIX), to expand an existing discovery collaboration that was signed in 2013.

Genentech and Immunocore will now co-develop Immunocore’s therapeutic candidate IMC-C103C, an ImmTACmolecule targeting tumors that express the protein MAGE-A4 (melanoma-associated antigen A4).

Under the terms of the agreement, Immunocore will lead the first-in-human clinical trial to establish safety and preliminary efficacy of IMC-C103C as both monotherapy and in combination with atezolizumab (Roche’s Tecentriq). The clinical trial, which is scheduled to commence in early 2019, will enrol patients across a number of solid tumour types.